We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00623142
Recruitment Status : Completed
First Posted : February 25, 2008
Last Update Posted : February 25, 2008
Information provided by:

February 14, 2008
February 25, 2008
February 25, 2008
January 2005
January 2007   (Final data collection date for primary outcome measure)
  • Myocardial Hsp72 protein [ Time Frame: Intra-operative (During CABG) ]
  • Myocardial eNOS protein [ Time Frame: Intra-Operative (During CABG) ]
  • Serum Troponin-T [ Time Frame: Peri-operative ]
  • Serum soluble ICAM-1 [ Time Frame: Peri-operative ]
  • Serum soluble PSGL-1 [ Time Frame: Peri-operative ]
  • Serum soluble P-Selectin [ Time Frame: Peri-operative ]
  • Serum soluble E-Selectin [ Time Frame: Peri-operative ]
Same as current
No Changes Posted
  • All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter [ Time Frame: Peri-operative ]
  • Duration of mechanical ventilation [ Time Frame: Post Operative ]
  • Duration of endotracheal intubation [ Time Frame: post operative ]
  • Length of stay in ICU [ Time Frame: Post-operative ]
  • Blood loss [ Time Frame: Post operative ]
  • Inotrope usage [ Time Frame: Post operative ]
  • Atrial Fibrillation [ Time Frame: Post operative ]
  • Low cardiac output status [ Time Frame: Post operative ]
  • Pulmonary complications [ Time Frame: Post operative ]
  • Renal Complications [ Time Frame: Post operative ]
  • Cerebrovascular complications [ Time Frame: Post operative ]
  • Gastrointestinal complications [ Time Frame: Post operative ]
  • Wound complications [ Time Frame: Post operative ]
  • Cost of ICU stay [ Time Frame: Post operative ]
Same as current
Not Provided
Not Provided
The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery
The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection & Ischemic Reperfusion Injury
The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.
Not Provided
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Health Services Research
  • Myocardial Reperfusion Injury
  • Cytoprotection
Drug: Hyperbaric Oxygen
100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Other Name: Hyperbaric Oxygen Preconditioning
  • No Intervention: A
    Patients in this arm were not treated with HBO prior to CABG
  • Experimental: B
    Patients in this arm were treated with HBO prior to CABG
    Intervention: Drug: Hyperbaric Oxygen

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2008
January 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients undergoing elective first time CABG
  • Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

Exclusion Criteria:

  • Age ≤ 20 years or ≥ 85 years
  • Ejection fraction < 30%
  • Unstable angina
  • Recent myocardial infarction (< 1 month)
  • Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)
  • Any end stage organ failure (e.g. renal and respiratory failure)
  • History of chronic obstructive pulmonary disease (COPD)
  • Pneumothorax
  • Pulmonary bullae
  • Convulsions
  • Current history of malignancy
  • Severe myopia or intraocular lens
  • Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.
Sexes Eligible for Study: All
20 Years to 85 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Dr. Jeysen Zivan Yogaratnam, Hull & East Yorkshire NHS Trust
Hull and East Yorkshire Hospitals NHS Trust
North of England Medical & Hyperbaric Services
Principal Investigator: Jeysen Z Yogaratnam, MB.BCh, BAO, MRCS Hull & East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom
Hull and East Yorkshire Hospitals NHS Trust
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP